Diabetes Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update

Description

GlobalData's Medical Devices sector report, "Diabetes Assays Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Diabetes Assays pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Diabetes Assays are tests to first diagnose diabetes and assess the risk of diabetes, such as pre-diabetes, through analysis of blood.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the Diabetes Assays under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Diabetes Assays and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Diabetes Assays under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date

Product Code: GDME1771EPD

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 Diabetes Assays Overview

3 Products under Development

3.1 Diabetes Assays - Pipeline Products by Stage of Development
3.2 Diabetes Assays - Pipeline Products by Segment
3.3 Diabetes Assays - Pipeline Products by Territory
3.4 Diabetes Assays - Pipeline Products by Regulatory Path
3.5 Diabetes Assays - Pipeline Products by Estimated Approval Date

4 Diabetes Assays - Pipeline Products under Development by Companies

4.1 Diabetes Assays Companies - Pipeline Products by Stage of Development
4.2 Diabetes Assays - Pipeline Products by Stage of Development

5 Diabetes Assays Companies and Product Overview

6 Diabetes Assays- Recent Developments

6.1 May 15, 2024: Advanced Screening Method for Early Detection of Type 1 Diabetes Exceeds Traditional Standards
6.2 Feb 21, 2024: World-First Introduction of Home Oral Glucose Tolerance Testing Service for Gestational Diabetes Sees University Hospital Southampton Improve Test Accessibility and Yield Maximum User Preference Scores
6.3 Feb 06, 2024: Beckman Coulter Diagnostics Appoints Kevin O'Reilly as New President
6.4 Jan 23, 2024: Enable Biosciences Enhances 'Kit to Clinics' With Rigorously Vetted Adap Technology for Diabetes Care
6.5 Jan 10, 2024: A New Study Shows Glycomark is a Novel Biomarker of SGLT-2I Adherence
6.6 Dec 19, 2023: Enable Biosciences Receives $3M Phase IIB SBIR Award From NIDDK for Advanced T1D Testing Technology
6.7 Nov 30, 2023: Switch Health develops Canada's first at-home diagnostic Diabetes test
6.8 Nov 17, 2023: New Research Center for Artificial Intelligence and Causal Methods in Medicine
6.9 Oct 30, 2023: New Clinical Data Point To Use of Glycomark as Biomarker of Sglt-2 Diabetes Drug Effectiveness and Compliance
6.10 Oct 19, 2023: Abbott Diagnostics Obtains Additional 510(k) Clearance for Afinion HbA1c Test

7 Appendix

7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer